Analyst Ratings for AbCellera Biologics (ABCL)
ABCL Rating Summary
ABCL Price Target Summary
- Highest: $7.00 (Stifel)
- Lowest: $4.00 (Leerink Partners)
- Average: $5.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$5.50 (+59.4%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 85%
Avg. $ Target:
$5.50 (+59.4%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 85%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/7/2025 | Leerink Partners | Faisal Khurshid | Downgrade | Market Perform (Outperform) |
4.00 (N/A) |
4.53 (3.45) |
-23.84% | Details |
| 8/20/2024 | Benchmark » Updated 8/13/2025 |
Robert Wasserman | Downgrade | Hold (Buy) |
N/A (N/A) |
2.71 (3.45) |
27.31% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
